Pharmacosmos

Denmark - HolbaekBiotechnology1 H-1B visas (FY2023)

Focus: Pharmacosmos is a Denmark-based biotech company founded in 2024, specializing in iron deficiency medicines with marketed products in oncology and hematology. The company is entirely dependent on COSELA (trilaciclib) for revenue generation.

Oncology Hematology

Profile data last refreshed 13h ago · AI intelligence enriched 2w ago

Open Jobs

About Pharmacosmos

AI assessmentNot Hiring

No open roles listed right now. Follow Pharmacosmos to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

3/9 — Basic

Company HealthStrong

Pipeline

Late-stage

25 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

COSELA

Oncology/Hematology

$80K Part D

Peak14.2yr

Only material revenue driver; smallest documented Part D spend ($80K) suggests early market penetration or niche label, but 16-year LOE window provides long runway.

Help build intelligence for Pharmacosmos

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Peak-stage marketed products (COSELA with LOE in 2040, MONOFERRIC in 2036) provide revenue stability and commercial infrastructure opportunities.
Extensive Phase 3 pipeline (10 ongoing programs) across iron deficiency indications (CKD, IBD, heart failure, pregnancy) offers clinical development and regulatory advancement visibility.
Focused therapeutic platform in iron metabolism creates deep domain expertise and potential for rapid indication expansion within a narrow, well-defined space.

Watch Out For

Company founded in 2024 with zero current active job openings signals either very early stage or acquisition/restructuring status—minimal near-term hiring visibility.
100% revenue concentration on COSELA creates existential dependence on a single drug; pipeline programs are earlier-stage (Phase 1–4) with no clear near-term catalysts.
No financial data, employee count, or funding information available; unable to assess cash runway, growth trajectory, or organizational stability.

Pipeline & Clinical Trials

Hepcidin as a Predictor for the IVI Mediated Increase in Haemoglobin Levels

Anemia

N/A

Clinical Trials (1)

NCT04263571Hepcidin as a Predictor for the IVI Mediated Increase in Haemoglobin Levels

N/A

5% Iron Isomaltoside 1000

Anaemia in Chronic Kidney Disease

N/A

Clinical Trials (1)

NCT02301026A Non-interventional Study of Diafer in Subjects With CKD on Haemodialysis for Treatment of Iron Deficiency

N/A

10% Iron Isomaltoside 1000

Iron Deficiency Anaemia

N/A

Clinical Trials (1)

NCT02546154Time to Relapse of Iron Deficiency Anaemia After Standard Treatment With The Intravenous Iron (Monofer®)

N/A

10% Iron Isomaltoside 1000

Iron Deficiency Anemia

N/A

Clinical Trials (1)

NCT01900197Time to Relapse of Iron Deficiency Anemia After Standard Treatment With a New Intravenous Iron (Monofer®)

N/A

Monofer

Inflammatory Bowel Disease

Phase 1

Clinical Trials (1)

NCT01213680Open-label PK Study of Iron Isomaltoside 1000 (Monofer) Administered by 500 mg IV Injection or 1000 mg IV Infusion to Patients With Inflammatory Bowel Disease

Phase 1

Monofer

Patients With Chemotherapy Induced Anemia (CIA)

Phase 1

Clinical Trials (1)

NCT01280240Pharmacokinetic Study of Iron Isomaltoside 1000 Administered by 250 mg IV Bolus Injection or 500 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia

Phase 1

Iron Isomaltoside

Anemia

Phase 1

Clinical Trials (1)

NCT03013439Dose-escalation Trial of the Safety, Pharmacokinetics, and Pharmacodynamics of Iron Isomaltoside (Monofer®)

Phase 1

Iron isomaltoside 1000

Non-dialysis Dependent Chronic Kidney Disease

Phase 1

Clinical Trials (1)

NCT01213992Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 500 mg IV Bolus Injection or 1000 mg Intravenous to Patients With CKD

Phase 1

500 mg iron isomaltoside 1000

Non-hematological Malignancies

Phase 1

Clinical Trials (1)

NCT01213979Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 500 mg IV Bolus Injection or 1000 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia (CIA)

Phase 1

Monofer®

Chronic Kidney Disease

Phase 1

Clinical Trials (1)

NCT01469078Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered as Single Bolus Injections in Subjects With Stage 5 Chronic Kidney Disease on Dialysis Therapy (CKD-5D)

Phase 1

Iron isomaltoside 1000

Restless Legs Syndrome

Phase 2

Clinical Trials (1)

NCT02484768IV Iron Treatment of Restless Legs Syndrome

Phase 2

SP-420

Beta Thalassemia Major Anemia

Phase 2

Clinical Trials (1)

NCT05693909A Trial Testing SP-420 in Subjects With Transfusion-dependent β-thalassemia or Low-risk Myelodysplastic Syndromes

Phase 2

Intravaneous iron

Pregnancy

Phase 2

Clinical Trials (1)

NCT02038023Intravaneous Iron(1000 mg Low Molecular Weight Iron Dextran Over 60 Minutes) for Pregnant Women

Phase 2

Iron Isomaltoside 1000

Heart Transplant Recipients

Phase 2/3

Clinical Trials (1)

NCT03662789Intravenous Iron Supplement for Iron Deficiency in Cardiac Transplant Recipients

Phase 2/3

Monofer

Peritoneal Dialysis

Phase 3

Clinical Trials (1)

NCT06884280Comparing High and Low Dose Iron Treatments for People on Peritoneal Dialysis: The PALaDIN Study

Phase 3

Ferric Derisomaltose

Chronic Heart Failure

Phase 3

Clinical Trials (1)

NCT06929806Multi-center Trial of Ferric Derisomaltose Versus no Intravenous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart Failure

Phase 3

Iron isomaltoside/ferric derisomaltose

Iron Deficiency Anaemia

Phase 3

Clinical Trials (1)

NCT03238911Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia

Phase 3

Monofer

Chronic Kidney Disease Stage 5 (Dialysis Dependent)

Phase 3

Clinical Trials (1)

NCT01222884A Randomized, Comparative, Open-label Study of IV Monofer® Administered as Maintenance Therapy by Single or Repeated Bolus Injections in Comparison With IV Iron Sucrose in Subjects With CKD-5D

Phase 3

Monofer

Iron Deficiency Anemia

Phase 3

Clinical Trials (1)

NCT01102413Iron Isomaltoside 1000 (Monofer®) in Non-Dialysis Dependent Chronic Kidney Disease and With Renal-Related Anaemia

Phase 3

Iron isomaltoside/ferric derisomaltose

Iron Deficiency Anemia

Phase 3

Clinical Trials (1)

NCT02962648An Extension Trial to Assess the Safety of Re-dosing of Iron Isomaltoside/Ferric Derisomaltose (Monofer®/Monoferric®)

Phase 3

Iron isomaltoside/ferric derisomaltose

Iron Deficiency Anaemia

Phase 3

Clinical Trials (1)

NCT03237065Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose or Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia

Phase 3

Iron isomaltoside 1000

Iron Deficiency Anemia

Phase 3

Clinical Trials (1)

NCT02172001A Randomized, Double-blind, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Against Placebo

Phase 3

Iron oligosaccharide

Chronic Kidney Disease

Phase 3

Clinical Trials (1)

NCT00536666A Study of Iron Oligosaccharide in Chronic Kidney Disease Patients

Phase 3

Iron isomaltoside/ferric derisomaltose

Iron Deficiency Anaemia

Phase 3

Clinical Trials (1)

NCT02940860Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney Disease

Phase 3

Ferric Derisomaltose Injection

Gynecologic Cancer

Phase 3

Clinical Trials (1)

NCT05467319Ferric Derisomaltose/Iron Isomaltoside and Outcomes in the Recovery of Gynecologic Oncology ERAS

Phase 3

Iron oligosaccharide

Heart Failure, Congestive

Phase 3

Clinical Trials (1)

NCT00537186A Study of Iron Oligosaccharide in CHF Patients

Phase 3

Iron Isomaltoside 1000

Inflammatory Bowel Disease

Phase 3

Clinical Trials (1)

NCT01599702Iron Isomaltoside 1000 (Monofer®) Administered by a High Dosing Regimen in Subjects With Inflammatory Bowel Disease

Phase 3

iron isomaltoside 1000

Non-myeloid Malignancies

Phase 3

Clinical Trials (1)

NCT01145638A Study of Intravenous Iron Isomaltoside 1000 (Monofer®) as Mono Therapy (Without Erythropoiesis Stimulating Agents) in Comparison With Oral Iron Sulfate in Subjects With Non-myeloid Malignancies Associated With Chemotherapy Induced Anaemia (CIA)

Phase 3

Iron isomaltoside 1000

Iron-deficiency

Phase 3

Clinical Trials (1)

NCT01895231A Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered by Infusions to Iron-deficient Blood Donors

Phase 3

iron isomaltoside 1000

Iron Deficiency Anaemia

Phase 3

Clinical Trials (1)

NCT02130063IDA-01 A Randomised, Open-Label, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) and Iron Sucrose

Phase 3

Iron isomaltoside 1000

Severe Postpartum Haemorrhage

Phase 3

Clinical Trials (1)

NCT01895205Treatment of Women After Severe Postpartum Haemorrhage

Phase 3

Monofer

Inflammatory Bowel Disease

Phase 3

Clinical Trials (1)

NCT01017614Iron Oligosaccharide in Inflammatory Bowel Disease Subjects With Iron Deficiency Anaemia

Phase 3

Iron isomaltoside/ferric derisomaltose

Iron Deficiency Anaemia

Phase 3

Clinical Trials (1)

NCT02940886Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA)

Phase 3

Monofer

Inflammatory Bowel Disease

Phase 3

Clinical Trials (1)

NCT01410435Safety and Efficacy Extension Study of Iron Isomaltoside 1000 (Monofer®) in Subjects With Inflammatory Bowel Disease

Phase 3

Ferric Derisomaltose 1000 Mg in 10 mL INTRAVENOUS SOLUTION [Monoferric]

Anemia, Iron Deficiency

Phase 3

Clinical Trials (1)

NCT05304442IV Iron Trial for Anemia Related to Uterine Bleeding in Female Patients Presenting to the Emergency Department

Phase 3

Ferric Derisomaltose

Iron Deficiency, Anaemia in Children

Phase 3

Clinical Trials (1)

NCT05179226Multi-center Trial of Ferric Derisomaltose in Children 0 to <18 Years of Age With Iron Deficiency Anemia

Phase 3

Trilaciclib

Limited Stage Small Cell Lung Cancer

Phase 3

Clinical Trials (1)

NCT07473128Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer

Phase 3

Iron isomaltoside 1000

Postpartum Haemorrhage

Phase 3

Clinical Trials (1)

NCT01895218Treatment of Women After Postpartum Haemorrhage

Phase 3

Iron isomaltoside 1000

Non-anaemic Patients Undergoing Cardiac Surgery

Phase 3

Clinical Trials (1)

NCT01563367A Prospective, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered by Infusions to Non-Anaemic Patients Undergoing Elective or Sub-Acute Coronary Artery Bypass Graft, Valve Replacement or a Combination Thereof

Phase 3

Monoferric

Anemia

Phase 4

Clinical Trials (1)

NCT05258825Preoperative Monoferric for Abdominal Surgery

Phase 4

Trilaciclib

Extensive-stage Small-cell Lung Cancer

Phase 4

Clinical Trials (1)

NCT05874401Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan

Phase 4

Ferric derisomaltose

Perioperative Anemia

Phase 4

Iron isomaltoside 1000

Anemia

Phase 4

Clinical Trials (1)

NCT01927328Iron Replacement in Oesophagogastric Neoplasia

Phase 4

Ferric Derisomaltose

Anemia Postoperative

Phase 4

Clinical Trials (1)

NCT04608539A Clinical Trial Assessing the Efficacy of Intravenous Iron for the Treatment of Anemia Following Cardiac Surgery

Phase 4

Ferric Derisomaltose

Chronic Heart Failure

Phase 4

Clinical Trials (1)

NCT02642562Intravenous Iron Treatment in Patients With Heart Failure and Iron Deficiency: IRONMAN

Phase 4

Ferric Derisomaltose 100 MG/ML

Iron Deficiency Anemia

Phase 4

Clinical Trials (1)

NCT04913649Intravenous Iron to Treat Postoperative Anemia in Older Cardiac Surgery Patients

Phase 4

Pentaisomaltose

Malignant Lymphoma

Phase 4

Clinical Trials (1)

NCT05545202A Randomized, Comparative, Double-blind Trial of Pentaisomaltose and Dimethyl Sulphoxide for Cryoprotection of Hematopoietic Stem Cells in Subjects With Multiple Myeloma or Malignant Lymphoma With a Need for Autologous Transplantation

Phase 4

Iron Isomaltoside

IBD

Phase 4

Clinical Trials (1)

NCT03466983A Trial Comparing the Incidence of Hypophosphatemia in Relation to Treatment With Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia Due to Inflammatory Bowel Disease

Phase 4

Ferric Derisomaltose 1000 Mg in 100 mL INTRAVENOUS SOLUTION [Monoferric]

Iron-deficiency

Phase 4

Clinical Trials (1)

NCT04945707Impact of Intravenous Iron Repletion On Mechanisms of Exercise InTolerance in HFpEF (IRONMET-HFpEF)

Phase 4

Iron isomaltoside

Anemia, Iron-Deficiency

Phase 4

Clinical Trials (1)

NCT02999217Intravenous Iron for Correction of Anaemia After Colorectal Surgery

Phase 4

Interview Prep Quick Facts

Founded: 2024

Portfolio: 2 approved products, 50 clinical trials

Top TAs: Hematology, Nephrology, Oncology

H-1B (2023): 1 approval

Portfolio Health

Peak2 (100%)

2 total products

Therapeutic Area Focus

Hematology

1 marketed21 pipeline

Nephrology

1 marketed8 pipeline

Oncology

1 marketed7 pipeline

Cardiovascular

1 marketed4 pipeline

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Pharmacosmos

About Pharmacosmos

Why Work Here

Key Products

Watch Out For

Products & Portfolio (2)

Key Products by Revenue

Other Products (1)

Pipeline & Clinical Trials

Open Jobs (0)

Visa Sponsorship